NCT04986579Phase 2Recruiting
Scalp Cooling in MBC
Assessing the Impact of Scalp Cooling in With Metastatic Breast Cancer
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 2
- Sponsor
- Dana-Farber Cancer Institute
- Participants (registry)
- 120
- Start
- October 2021
- Primary completion
- June 2028 (planned)
- Study completion
- June 2030 (planned)
- Last registry update
- June 2026
- Countries
- United States
Conditions studied: Metastatic Breast Cancer, Chemotherapy-induced Alopecia
Interventions: Paxman Scalp Cooling System, Scalp Cooling Cap, Eribulin, Halaven, Sacituzumab govitecan, Trodelvy, IMMU-132, Trastuzumab deruxtecan, Enhertu, DS-8201a
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.